Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.
Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.
A difference is not always a contradiction
Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.
451 matching notes. Showing 289-304; page 19 of 29.
NIPRIDE RTU: mean infusion rate and thiocyanate risk
The renal and anuric limits refer to mean infusion rate. Thiocyanate removal must not be confused with clearance of cyanide.
What to reconcile
Retain renal status, duration and toxicity monitoring; do not reword a mean-rate limit as an instantaneous universal maximum.
1 source identities and dates
GlobalRPh RX List - NIPRIDE RTU
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Sodium nitroprusside - NIPRIDE RTU renal limits; selected source sections, not a full prescribing monograph.
SPINRAZA: urine protein concentration is not a ratio
The selected trigger is a urine protein concentration, with repeat testing and evaluation. It is not a urine protein/creatinine ratio or a renal dose-reduction rule.
What to reconcile
Keep the specimen, units and pre-dose testing schedule explicit.
1 source identities and dates
GlobalRPh RX List - SPINRAZA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Nusinersen - SPINRAZA intrathecal injection; selected source sections, not a full prescribing monograph.
MYCAPSSA: oral maintenance has a distinct ESRD starting instruction
The oral capsule maintenance pathway differs from injectable octreotide schedules, including the ESRD starting frequency.
What to reconcile
Match oral maintenance eligibility, food timing and IGF-1-guided titration; do not borrow an injectable regimen.
1 source identities and dates
GlobalRPh RX List - MYCAPSSA
GlobalRPh-hosted RX List | Source revision: RX page prints July 2024. MYCAPSSA oral delayed-release capsules for long-term maintenance of acromegaly after response and tolerance to octreotide or lanreotide.
Reduced dialysis clearance is not an automatic percentage reduction
Immediate-release injection supplies a maintenance-adjustment caution without a complete numerical dialysis regimen.
What to reconcile
Retain this uncertainty and consult the appropriate product source; do not substitute LAR or oral initiation instructions.
1 source identities and dates
GlobalRPh RX List - SANDOSTATIN injection
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. SANDOSTATIN immediate-release octreotide injection; not LAR DEPOT or oral octreotide.
SANDOSTATIN LAR: dialysis starting dose is not a permanent ceiling
The depot renal instruction concerns initiation. Maintenance and short-acting overlap remain indication-specific.
What to reconcile
Confirm depot formulation, prior short-acting treatment and the indication-specific transition. Do not apply the depot starting dose to oral octreotide.
1 source identities and dates
GlobalRPh RX List - SANDOSTATIN LAR DEPOT
GlobalRPh-hosted RX List | Source revision: RX page prints July 2024. Octreotide - SANDOSTATIN LAR DEPOT injection; selected source sections only, not a complete prescribing monograph.
The introductory adjustment trigger is <50, but the first table band includes 20-50. The dose unit remains indication-specific.
What to reconcile
Resolve exactly 50 against the applicable current product and institutional policy instead of silently assigning it.
1 source identities and dates
GlobalRPh RX List - FLOXIN
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Systemic oral ofloxacin, not otic or ophthalmic products. Historical infection indications require current treatment-policy review.
TRYNGOLZA: CKD-EPI name does not repair missing printed indexing
The source names CKD-EPI while its selected units omit the BSA denominator; severe impairment remains unstudied.
What to reconcile
Do not silently relabel or convert the metric or extend the supported range.
1 source identities and dates
GlobalRPh RX List - TRYNGOLZA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Olezarsen - TRYNGOLZA injection; selected source sections only, not a complete prescribing monograph.
OLINVYK: no adjustment does not remove opioid risk
A renal no-adjustment statement and a small ESRD PK study do not remove respiratory-depression precautions.
What to reconcile
Use complete opioid titration and safety instructions; do not infer a dialysis supplement.
1 source identities and dates
GlobalRPh RX List - OLINVYK
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Oliceridine - OLINVYK intravenous injection; selected source sections only, not a complete prescribing monograph.
TRIBENZOR: combination restriction overrides a component-only inference
An olmesartan-only no-initial-adjustment statement does not establish fixed-combination eligibility.
What to reconcile
Assess the complete product, not just the angiotensin receptor blocker component.
1 source identities and dates
GlobalRPh RX List - TRIBENZOR
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Olmesartan / amlodipine / hydrochlorothiazide - TRIBENZOR; selected source sections only, not a complete prescribing monograph.
SKYCLARYS: observed and expected renal ranges are different
The observed eGFR threshold and expected mild-impairment category are not the same evidence statement.
What to reconcile
Keep observed PK findings separate from extrapolation and unknown moderate/severe effects.
1 source identities and dates
GlobalRPh RX List - SKYCLARYS
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Omaveloxolone - SKYCLARYS capsules; selected source sections only, not a complete prescribing monograph.
ORBACTIV and KIMYRSA: same ingredient, different infusion instructions
ORBACTIV has its own preparation and infusion schedule. Lack of HD removal does not supply a dedicated severe-renal study.
What to reconcile
Use one complete product-specific regimen; do not combine preparation or infusion instructions from the two products.
1 source identities and dates
GlobalRPh RX List - ORBACTIV
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Oritavancin - ORBACTIV intravenous infusion; selected source sections only, not a complete prescribing monograph.
No routine renal adjustment does not remove heparin restrictions
Mild/moderate renal dosing guidance coexists with a 120-hour IV unfractionated-heparin contraindication due to aPTT interference.
What to reconcile
Reconcile the anticoagulant and monitoring plan with the dialysis team before treatment. A renal dose table alone is insufficient.
1 source identities and dates
GlobalRPh RX List - KIMYRSA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. KIMYRSA IV product; assess dialysis anticoagulants and laboratory interference before use.
CAPD threshold differs between the mirror and official label
The mirror CAPD row prints below 10 mL/min; the dated official label includes 10 or below. Treatment and prophylaxis schedules also differ.
What to reconcile
Preserve the discrepancy; use the exact population, modality and indication. Do not transfer CAPD guidance to automated PD or CRRT.
2 source identities and dates
GlobalRPh RX List - TAMIFLU
GlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval TAMIFLU adult renal table; influenza treatment and prophylaxis are distinct.
ISTURISA: no renal dose adjustment does not remove the cortisol-assay caveat
Both selected sources pair no renal dose adjustment with caution interpreting urinary free cortisol in moderate or severe impairment.
What to reconcile
Retain the monitoring limitation during endocrine assessment and titration.
2 source identities and dates
GlobalRPh RX List - ISTURISA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Adult oral osilodrostat; selected renal and monitoring information, not a complete titration protocol.
VIVJOA: severe-renal source disagreement is not resolved by a date assumption
The RX mirror permits severe impairment; retrieved DailyMed and manufacturer safety wording do not. The mirror prints April 2024; DailyMed has a January 2026 header but an April 2022 PI revision.
What to reconcile
Hold the more permissive RX instruction for exact-label reconciliation. Do not treat header/retrieval dates as new label revisions or prescribe from the disputed extract.
2 source identities and dates
GlobalRPh RX List - VIVJOA
GlobalRPh-hosted RX List | Source revision: RX page prints April 2024; not independently reconciled to an FDA label revision. Oteseconazole - VIVJOA capsules; selected source sections only, not a complete prescribing monograph.
DailyMed / Mycovia Pharmaceuticals, Inc. | Source revision: Prescribing information revised April 2022. VIVJOA - official renal restriction summary; selected source sections only, not a complete prescribing monograph.
VIVJOA: official recheck retains the disagreement hold
The current RX recheck remains permissive in severe impairment; the retrieved DailyMed renal section remains restrictive. Header and retrieval dates do not establish a new prescribing-information revision.
What to reconcile
Continue holding the disputed RX instruction. This release does not claim exact controlling-label reconciliation.
2 source identities and dates
GlobalRPh RX List - VIVJOA
GlobalRPh-hosted RX List | Source revision: RX page prints April 2024; not independently reconciled to an FDA label revision. Oteseconazole - VIVJOA capsules; selected source sections only, not a complete prescribing monograph.
DailyMed / Mycovia Pharmaceuticals, Inc. | Source revision: Previously established PI revision April 2022; section 8.6 and header rechecked in v5.0. VIVJOA - official renal discrepancy recheck; selected renal passages, not a complete prescribing monograph.
Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.